Abstracts Archive - Page 2332 of 2425 - ACR Meeting Abstracts

Abstract Number: 1340 • 2012 ACR/ARHP Annual Meeting
Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael H. Schiff², Michael E. Weinblatt³, Michael A. Maldonado⁴, Elena M. Massarotti⁵ and Yusuf Yazici⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology Division, University of Colorado, Denver, CO, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴Medical Strategy, Bristol-Myers Squibb, Princeton, NJ, ⁵Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶New York University, New York, NY
Background/Purpose: Advancements in the understanding of Rheumatoid Arthritis (RA) have led to the development of novel therapeutics and treatment guidelines that target remission as an…
Abstract Number: 1341 • 2012 ACR/ARHP Annual Meeting
Beneficial Effect of Anti-TNF Therapy in the Lipoprotein Atherogenic Risk Profile in Comparison with DMARD Standard Therapy in RA Patients
Jaime Calvo-Alen¹, Ignacio Villa², Victor M. Martinez-Taboada³, Jose Luis Peña-Sagredo⁴, Mario Agudo⁴, Ana Carmen García⁵ and Juan Gomez-Gerique⁶, ¹Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ²Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, ³Rheumatology, Hospital Universitario Marques de Valdecilla. IFIMAV, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Fundación 12 de Octubre, Madrid, Spain, ⁶Laboratorio de metabolismo lípidico y riesgo vascular, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: RA patients portend a greater risk of cardio-vascular complications than general population. Although most probably diverse mechanisms are implicated, quantity and quality changes in…
Abstract Number: 1342 • 2012 ACR/ARHP Annual Meeting
Changes in Patient Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael E. Weinblatt², Michael H. Schiff³, Dinesh Khanna⁴, Daniel Furst⁵ and Michael A. Maldonado⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Rheumatology Division, University of Colorado, Denver, CO, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁶Medical Strategy, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Rheumatoid arthritis (RA) is associated with pain, fatigue, disability and functional loss, which can significantly impact a patient's health-related quality of life (HRQoL). Patient-Reported…
Abstract Number: 1343 • 2012 ACR/ARHP Annual Meeting
EARLY Improvements in the Lower Limbs Enthesis by Ultrasound Predicting Later Favorable Responses in TNF Inhibotors-Treated Patients with Spondyloarthritis
Kensuke Kume¹, Kanzo Amano¹, Kuniki Amano², Hiroyuki Ohta³ and Noriko Kuwaba⁴, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Sky Clinic, Hiroshima, Japan, ³Medical Research, hiroshima clinic, Hiroshima, Japan, ⁴Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Lower limbs enthesis by ultrasound (US) detects inflammatory activity in patients with spondyloarthritis(SpA) and is a diagnostic tool of early SpA. The present objective…
Abstract Number: 1344 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of High Sensitivity C Reactive Protein for Early Axial Spondyloarthritis: Results From the Devenir Des Spondylarthopathies Indifferenciees Recentes Cohort
Victoria Navarro-Compán¹, Désirée van der Heijde², Bernard Combe³, Claudine Cosson⁴ and Floris van Gaalen¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Deptartment of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Biochemistry, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: The average delay in spondyloarthritis (SpA) diagnosis after symptom onset is one of the longest among the inflammatory rheumatic diseases. Elevated C-reactive protein (CRP)…
Abstract Number: 1345 • 2012 ACR/ARHP Annual Meeting
Validation of the Health Assessment Questionnaire for Spondyloarthritis in Patients with Non-Radiographic Axial Spondyloarthritis
Dennis Revicki¹, Wen-Hung Chen¹, Ying Jin¹, Sumati Rao², Philip J. Mease³ and Mary Cifaldi², ¹United Biosource Corporation, Bethesda, MD, ²Abbott Laboratories, Abbott Park, IL, ³Swedish Rheumatology Research Group, Seattle, WA
Background/Purpose: To evaluate the psychometric properties of the Health Assessment Questionnaire for Spondyloarthritis (HAQ-S) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Methods: Data from 185…
Abstract Number: 1346 • 2012 ACR/ARHP Annual Meeting
Comparison of Three Screening Tools in Psoriatic Arthritis: The Contest Study
Laura C. Coates¹, Tariq Aslam¹, A. D. Burden², Esther Burden-Teh³, Anna R. Caperon⁴, Rino Cerio⁵, Chandra Chattopadhyay⁶, Hector Chinoy⁷, Mark J. D. Goodfield⁸, Lesley Kay⁹, Bruce W. Kirkham¹⁰, Christopher R. Lovell¹¹, Helena Marzo-Ortega¹², Neil McHugh¹³, Ruth Murphy³, Costantino Pitzalis¹⁴, NJ Reynolds¹⁵, Catherine H. Smith¹⁶, Elizabeth Stewart¹⁷, Richard B. Warren¹⁸, Hilary E. Wilson¹⁹ and Philip S. Helliwell²⁰, ¹LIMM, University of Leeds, Division of Rheumatic and Musculoskeletal Disease, LIMM, University of Leeds, Leeds, United Kingdom, ²Department of Dermatology, Western Infirmary, Dumbarton Road, United Kingdom, ³Department of Dermatology, Nottingham Independent Treatment Centre, Nottingham, United Kingdom, ⁴Division of Rheumatic and Musculoskeletal Disease, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁵CMS/CAU Cutaneous Medicine and Surgery, Bart's and The London NHS Tust, United Kingdom, ⁶Department of Rheumatology, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom, ⁷Rheumatic Diseases Centre, The University of Manchester, Manchester, United Kingdom, ⁸Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁹Department of Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ¹⁰Rheum Dept/ Guys Hospital, 4th Fl Thomas Guy House, London, United Kingdom, ¹¹Department of Dermatology, Royal United Hospital, Bath, United Kingdom, ¹²Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, United Kingdom, ¹³Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom, ¹⁵Department of Dermatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ¹⁶St John's Institute of Dermatology, Guys and St Thomas' Hospital, London, ¹⁷Department of Dermatology, Wrightington, Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom, ¹⁸Dermatology Centre, University of Manchester, Manchester, United Kingdom, ¹⁹Department of Rheumatology, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, ²⁰PsAID taskforce, EULAR, Zurich, Switzerland
Background/Purpose: The majority of patients with PsA have psoriasis prior to arthritis and there is evidence that a significant proportion of patients in dermatology clinics…
Abstract Number: 1347 • 2012 ACR/ARHP Annual Meeting
Anti-TNFá Discontinuation in Psoriatic Arthritis: Is It Possible After Achieving Minimal Disease Activity?
Amir Haddad¹, Arane Thavaneswaran¹, Vinod Chandran² and Dafna D. Gladman³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Remission in Psoriatic Arthritis, defined as a period of at least 3 consecutive visits with no actively inflamed joints, occurs in about 17 percent…
Abstract Number: 1348 • 2012 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Psoriatic Arthritis
Amir Haddad¹, Arane Thavaneswaran¹, Sergio M.A. Toloza², Vinod Chandran³ and Dafna D. Gladman⁴, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Medicine, Hospital San Juan Bautista, Catamarca, Argentina, ³Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Spondylitis in Psoriatic Arthritis (PsA) sometimes resembles DISH because of the presence of juxta-vertebral calcification that resemble syndesmophytes. Distinguishing spondylitis from DISH has therapeutic…
Abstract Number: 1349 • 2012 ACR/ARHP Annual Meeting
Trends in Incidence and Clinical Features of Ankylosing Spondylitis in Olmsted County (1980-2009): A Population Based Study
Kerry Wright¹, Cynthia S. Crowson², Clement J. Michet¹ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: To determine trends in the incidence and clinical presentation of ankylosing spondylitis (AS) among residents of a geographically defined area first diagnosed 1980-2009 and…
Abstract Number: 1350 • 2012 ACR/ARHP Annual Meeting
Inflammatory Biomarkers in Psoriatic Arthritis
Ibrahim AlHomood¹, Arane Thavaneswaran¹, D. D. Gladman² and Vinod Chandran³, ¹Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis that may progress rapidly and result in joint damage and disability. The aim of this study was…
Abstract Number: 1351 • 2012 ACR/ARHP Annual Meeting
Ultrasonographic Entheseal Abnormalities Among Patients with Psoriatic Arthritis, Psoriasis Alone and Healthy Individuals and Their Correlation with Disease-Related Variables
Lihi Eder¹, Jai Jayakar², Arane Thavaneswaran³, Amir Haddad³, Daniel Pereira³, Sutharshini Shanmugarajah³, David Salonen⁴, Cheryl Rosen⁵, Vinod Chandran⁶ and Dafna D. Gladman⁷, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Medicine, University of Western Ontario, London, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Department of Medical Imaging, University Health Network, Toronto, ON, Canada, ⁵Division of Dermatology, University of Toronto, Toronto western Hospital, Toronto, ON, Canada, ⁶Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁷Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Enthesitis is an important manifestation of psoriatic arthritis (PsA). We aimed to compare the frequency of ultrasonographic (US) entheseal abnormalities between patients with PsA,…
Abstract Number: 1352 • 2012 ACR/ARHP Annual Meeting
Adalimumab Significantly Reduces Recurrence Rate of Anterior Uveitis in Patients with Ankylosing Spondylitis
J. Christiaan van Denderen¹, Ingrid M. Visman¹, M. T. Nurmohamed², Maria S.A. Suttorp-Schulten³ and Irene E. van der Horst-Bruinsma⁴, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, ³Ophtalmology, Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose : A high percentage (30-40%) of patients with Ankylosing Spondylitis (AS) suffer from acute anterior uveitis (AAU) attacks. Local treatment with corticosteroids is a…
Abstract Number: 1353 • 2012 ACR/ARHP Annual Meeting
Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Nonradiographic Axial Spa: Wk-52 Results From Ability-1
Désirée van der Heijde¹, Philip J. Mease², Aileen L. Pangan³, Sumati Rao⁴, Naijun Chen⁴ and Mary A. Cifaldi⁴, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Swedish Rheumatology Research Group, Seattle, WA, ³Abbott, Abbott Park, IL, ⁴Abbott Laboratories, Abbott Park, IL
Background/Purpose: To evaluate long-term effects of adalimumab (ADA) treatment on patient reported outcomes (PROs) in nonradiographic axial spondyloarthritis (nr-axSpA). Methods: Ability-1 is an ongoing Phase…
Abstract Number: 1354 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Psoriatic Arthritis Based On Rheumatologists’ Clinical Assessment Before and After Laboratory and Radiographic Tests in Psoriasis Patients in European/North American Dermatology Clinics
Dafna D. Gladman¹, Philip J. Mease², Rafat Y. Faraawi³, Eustratios Bananis⁴, Andrew S. Koenig⁵, Robert Northington⁴, Joanne Fuiman⁴ and Daniel Alvarez⁴, ¹Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, Canada, ²Division of Rheumatology Research, Swedish Medical Center, Seattle, WA, ³McMaster University, Hamilton, ON, Canada, ⁴Specialty Care, Pfizer Inc., Collegeville, PA, ⁵Specialty Care Business Unit, Pfizer Inc., Collegeville, PA
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease with a heterogeneous presentation that is associated with impaired quality of life, joint damage, and limited…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].